Article

KDM4A promotes the progression of neuroendocrine prostate cancer

2022-05-14

Abstract excerpt

<h4>ABSTRACT</h4> Neuroendocrine prostate cancer (NEPC) represents one of the most lethal forms of prostate cancer (PCa) and lacks life-prolonging treatment. The incidence of NEPC is increased due to the widespread use of AR pathway inhibitors (ARPIs) in the treatment of non-metastatic CRPC and hormone-sensitive metastatic tumors. Here, we identified histone lysine demethylase KDM4A as a key player in NEPC progre...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9d1b9211-cc06-5716-8938-81b7752f2985
DOI: 10.1101/2022.05.14.491739

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

KDM4A promotes the progression of neuroendocrine prostate cancerDOI 10.1101/2022.05.14.491739Read

Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancerSemantic proximity Read

Therapeutic Targeting of Histone Lysine Demethylase KDM4B Blocks the Growth of Castration-Resistant Prostate CancerSemantic proximity Read

Targeting the KDM4B–AR–c‐Myc axis promotes sensitivity to androgen receptor‐targeted therapy in advanced prostate cancerSemantic proximity Read

Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancerSemantic proximity Read

A MYC Family Switch: L-MYC Drives and Maintains Neuroendocrine Lineage Programs in Prostate CancerSemantic proximity Read

A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancerSemantic proximity Read

Histone Demethylase KDM5C Drives Prostate Cancer Progression by Promoting EMTSemantic proximity Read

Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate CancerSemantic proximity Read

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug TargetsSemantic proximity Read

Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitorsSemantic proximity Read

LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase functionSemantic proximity Read

N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancerSemantic proximity Read